Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.
D000328:Adult; D001665:Binding Sites; D001796:Blood Protein Disorders / Q000188:drug therapy* / Q000209:etiology; D002994:Clofibrate / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D009404:Nephrotic Syndrome / Q000150:complications*; D011141:Polyuria / Q000139:chemically induced; D012709:Serum Albumin / Q000378:metabolism; D000637:Transaminases / Q000097:blood
D008074:Lipoproteins; D012709:Serum Albumin; D000637:Transaminases; D005634:Fructose-Bisphosphate Aldolase; D002994:Clofibrate